Abstract 4211
Background
To analyze patterns of failure for patients with LA-NSCLC receiving definitive chemoradiotherapy and build a nomogram for predicting the failure patterns in these patients.
Methods
Clinicopathological materials of patients between 2013 and 2016 with LA-NSCLC receiving definitive chemoradiotherapy and following-up in our hospital were collected. The endpoint was the first failure after definitive chemoradiotherapy. Based on logistic regression, the predictive value of each factor was evaluated and nomogram was built. This model was validated by ROC curve, calibration curve and decision curve analysis (DCA).
Results
With a median follow-up of 28 month, 100 patients were observed failure. Local failure and distant failure were 46 and 54, respectively. Univariate and multivariate analysis indicated that younger (p = 0.016, OR (95%CI): 0.936 (0.887-0.987)), peripheral NSCLC (p = 0.025, OR (95%CI): 2.732 (1.137-6.567)) and epidermal growth factor receptor (EGFR) mutant (p = 0.020, OR (95%CI): 3.747 (1.234-11.381)) were independent predictors of distant failure, which were included in the nomogram. ROC curve showed that area under the ROC curve (AUC) of the nomogram was 0.713, which was better than any factors along. Calibration curve revealed a satisfactory consistency between the predicted distant failure and actual observation. DCA showed most of the threshold probabilities in this model were with good net benefits.
Conclusions
We concluded that age, tumor location and EGFR mutation status could predict failure patterns in patients with LA-NSCLC receiving definitive chemoradiotherapy. A nomogram was built and validated based on these factors, showing a potential predictive value in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract